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ABSTRACT 
 
 
Dan Yi, M.S. Department of Pharmacology and Toxicology, Wright State 
University, 2013. Tolfenamic Acid Induces Cell Apoptosis and Inhibits 
Collagen Accumulation in Keloid Fibroblasts. 
 
 
 
Keloid scar is a fibroproliferative disorder which results from the accumulation 
of collagen through the activation of TGF-ß/Smad signaling. Tolfenamic acid 
(TA) has been found to inhibit collagen synthesis in animal and induce cancer 
cell apoptosis. In this study, we investigated the effect of DMSO on cell 
apoptosis, TA on collagen deposition, and TA on collagen type I and smad2 
protein expression in human normal fibroblasts (NFs) and human keloid 
fibroblasts (KFs). In the dose- and exposure time- response assays, we found 
that 1% DMSO for 48h treatment did not obviously induce NF and KF 
apoptosis and that 0.55x10-3 M TA for 48h treatment remarkably decreased 
NF and KF proliferation. Under these experimental conditions, we further 
found that TA selectively induced cell apoptosis, strikingly decreased collagen 
production, and effectively inhibited collagen type I expression in KFs. Our 
data suggested that TA induces cell apoptosis and inhibits collagen 
accumulation in KFs. 
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I. INTRODUCTION 
 
Keloid scar, keloids, (Figure 1) is a raised scar which forms by expanding 
beyond the boundaries of the original lesion [1]. The main histological 
manifestation of a keloid scar (Figure 2) is the overgrowth of atypical 
fibroblasts with excessive accumulation of extracellular matrix components, 
especially collagen, fibronectin, elastin, and proteoglycans[1-4]. The causes of 
this type of scar are still unknown, but it has been pointed out that keloid scar 
can be developed after any dermal abrasion including burns, piercing, or 
surgery [1-6]. Accompanied with the development of keloids, are pimples, 
insect bites, scratching, and/or other skin trauma. The clinical symptoms of 
keloid scar are claw-like growths over normal skin, itching, pain, ulcerate after 
infection, deformity and joint movement difficulty [5, 6]. Currently, treatments of 
KFs contain the combination of excision followed by plastic surgery 
constructive procedures and 5-Fluorouracil with glucocorticoids injections 
followed by compression therapy using silicone sheets [1, 2]. Nonetheless, the 
recurrence remains 45%-100% [3, 4]. Moreover, it is difficult to develop animal 
models that mimic keloids as keloid scars are unique to humans [5]. So the 
treatment of keloids continue to be a great challenge for the reconstructive 
surgeon. 
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Figure 1. Keloid scar formation after left earlobe piercing. The formation of this 
type of scar behaves like a benign tumor with growing beyond the boundary of 
its original wound site.  
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Figure 2. Histological changes of human keloid scar tissue. Comparing with 
the histological manifestation of human normal dermal tissue, the fibroblasts 
are over growing with the excessive accumulation of extracellular connective 
components including collagen, fibronectin, elastin, proteoglucans. 
Keloid Scar adapted from PatelP.A., et al. 2011, Normal Dermal Tissue 
adapted from El-Aal, et al., 2012. 
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Normal Wound Healing 
 
Normal wound healing, cicatrisation, is a complicated process for the skin to 
repair itself after injury [7]. This procedure is a dynamic and interactive process 
with 4 phases: hemostasis, inflammation, proliferative and tissue remodeling [8, 
9]. After injury occurred, thrombocytes deposited at the lesion to form a fibrin 
clot to control active bleedingin first minutes [7, 8]. Then bacteria and debris 
are phagocytosed and removed from circulation to reconstruct the barrier built 
by epidermis and dermis. Next, vascular endothelial cells formed new blood 
vessels with a new provisional extracellular matrix (ECM) composed of 
fibroblasts with excreting collagen and fibronectin [8, 10, 11]. Concurrently, 
epidermis re-epithelialized and the proliferative cells atop the wound bed to 
cover the new tissue [7]. Finally, new born tissue remodeled with collagen 
which realigned along tension lines and later unneeded cells were removed by 
apoptosis [8]. 
 
The Formation of Keloid Scar  
 
Differing from normal wound healing, keloid scar formation begins with 
abnormal tissue growth in the dermal lesion extending beyond the borders of 
the original wound [9, 12-15]. In contrast, keloid scar mainly occurred with the 
abnormal fibroplasias and granulation formation of dermis and subcutaneous 
tissue in wound healing proliferative phase [16]. The pathological wound 
healing response of keloid scar composed of a high density of mesenchymal 
cells called keloid fibroblasts (KFs) [13, 14]. Consequently, the over growth of 
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KFs results in over-abundance of extracellular and intracellular matrix stroma, 
which is classified by irregularly directed and thick hyalinized spiral bundles 
described as keloidal collagen [5, 17]. During the formation of keloid scar, the 
type of collagen initially produced by fibroblasts was type III collagen. Within 
the maturation of keloid scar, collagen type I gradually replaces collagen type 
III and eventually formed extracellular matrix with 99% in the wound bed [1, 5, 
12-15, 17]. Finally, functionless tissue regeneration after skin trauma known as 
keloid scar formed [5, 15, 16, 18]. 
 
Keloid Characteristic Changes in TGF-ß/Smad Signaling Pathway 
 
Though the underlying mechanism of keloid scar formation remains unclear, 
studies have demonstrated the essential role of transforming growth 
factor-beta (TGF-ß) signaling pathway in the pathogenesis of keloid scar [14, 
15, 19]. The intracellular and extracellular signaling pathways of keloid scar 
formation mediated the relevant profibrotic TGF-ß responses [13, 16, 20]. 
Overproduction of intracellular and extracellular matrix through TGF-ß 
signaling activation could be responsible for the occurrence of keloid scar. As 
a multifunctional cytokine family, TGF-ß, activin, and bone morphogenetic 
protein, play crucial roles in regulating cellular responses such as proliferation, 
differentiation, immigration, apoptosis and biosynthesis of connective tissue 
[16, 20]. Dysregulation of the signaling transduction could cause a number of 
human diseases, e.g. fibrosis, vascular disorders, cancer, etc [5, 12, 21]. In 
TGF-ß signaling pathway, TGF-ß activates TGF-ß receptors to promote its 
downstream effective molecules, including members of the Drosophila Similar 
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to Mothers Against Decapentaplegic (Smad) family (Figure 3) [9, 18]. The 
smad family which is classified as receptor-regulated Smads (R-Smads: 
Smad1, 2, 4, 5 and 8), common mediator Smad (Co- Smad: Smad4), and 
inhibitory Smads (I-Smads: Smad6 and 7) is one of the dominant intracellular 
signaling mediators activated by TGF-ß receptors [18]. In TGF-ß signaling 
pathway, smad2 and smad3 are two critical conductive factors affecting 
nuclear gene expression [5, 16, 21, 22]. The involvement of TGF-ß/Smad 
signaling on keloid pathogenesis has been illustrated in some studies [16, 21, 
22]. It has been pointed out that smad family is involved in pathological fibrosis 
through phosphorylating Smad2/3 hetero-oligomeric complex which is 
consequently translocated from the cytoplasm to the nucleus to affect the 
synthesis and expression of collagen type I [12, 19]. In addition, smad pathway 
has also been shown to influence the expression of collagen type I in human 
glomerular mesangial cells and human mesangial cells [12, 19, 23]. Thus, 
suppressing smad2 expression could contribute to abnormal TGF-ß responses 
of fibroproliferation in keloid scar [5, 17, 19, 21, 23]. Therefore, the 
TGF-ß/Smad signaling pathway is a potential target for treating keloid 
fibroblasts. 
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Figure 3. TGF-ß/Smad signaling pathway plays an essential role in regulating 
collagen production in keloid fibroblasts. In keloid scar, TGF-ß signaling are 
upregulated. Representatives of smad family such as smad2, smad3, and 
smad4 are the transduction downstream of TGF-ß signaling pathway. With the 
upregulation of TGF-ß, the complexes of smad2/3/4 will bind to the nucleus 
which will cause an increase in gene expression. Meanwhile, the balance 
between collagen synthesis and degradation is interrupted. Eventually, 
expressed collagen increases and forms keloid scar with extracellular matrix. 
Modified from Tuan and Nicher, 1998. 
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The Studies of Tolfenamic Acid 
 
Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug (NSAIDs) that is 
traditionally used for rheumatic disease [24,25]. NSAIDs are non-prescription 
analgesics and antipyretics which are available over the counter in most 
countries [25, 26]. The representative members of NSAIDs are aspirin, 
ibuprofen, and naproxen, all of which are used as a non-addictive alternative to 
narcotics [26]. The dominate medical use of this group of drug are rheumatoid 
arthritis, osteoarthritis, Inflammatory arthropathies, acute gout, dysmenorrhoea, 
metastatic bone pain, headache and migraine, postoperative pain, 
mild-to-moderate pain due to inflammation and tissue injury, muscle stiffness 
and pain due to Parkinson's disease, pyrexia, renal colic, etc [27-30]. The main 
adverse effects of NSAIDs are gastrointestinal and renal effects such as ulcer 
perforation, upper gastrointestinal bleeding, nausea, vomiting, dyspepsia, 
diarrhea, salt and fluid retention, hypertension, interstitial nephritis, 
nephriticsyndrome, acute renal failure, acute tubular necrosis, etc [30, 31]. 
Alike many medicine, there are drug interactions between NSAIDs and others: 
inhibiting the elimination of lithium and methotrexate when using with diuretics, 
causing severe hypocoagulability when combining with warfarin, could 
aggravate hypertension when adding with antihypertensives, could interfere 
and reduce efficiency of antidepressants, etc [28, 30-32]. Majority of NSAIDs 
are functional as non-selectively inhibiting both the cyclooxygenase-1 (COX-1) 
andcyclooxygenase-2 (COX-2) isoenzymes [33]. COX-1 is a constitutively 
expressed "house-keeping" enzyme which regulates many cellular 
physiological responses [26, 34]. COX-2 is an enzyme expressed to 
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down-regulate inflammation symptoms [35, 36]. With the deeper studies 
reported on NSAIDs, it has been divided into different groups: salicylates, 
propionic acid derivatives, acetic acid derivatives, enolic acid derivatives; 
fenamic acid derivatives, and others. TA belongs to the family of fenamic acid 
derivatives. TA, 2-([3-Chloro-2-methylphenyl] amino) benzoic acid, with a low 
solubility in water, it is written out as C14H12ClNO2 (Figure 4.) and it has a 
molecular weight of 261.7 g/mol. The exact medical application, adverse 
effects, and mechanism of TA are not clear, however, previous studies have 
shown the special application of TA. Studies illustrated that TA was associated 
with inhibiting collagen metabolism in connective tissue in rats and had the 
capacity of inducing cancer cell apoptosis [24, 25, 37-42]. There is a low 
inhibition of sodium tolfenamate on the metabolism of collagen with 0.15 mol/L 
NaCl in rats [24]. Additionally, in vascular endothelial growth factor receptor 
1-dependent pancreatic cancer cell, cell migration determined by 
collagen–coated plates was inhibited by TA [42, 43]. TA could reduce cell 
survival, growth and angiogenesis in tumor and cancer cells, including human 
xenograft tumor, human pancreatic cancer, human neuroblastoma and mouse 
prostate cancer by regulating the activity of specific protein 1; human head and 
neck cancer by regulating non-steroidal anti-inflammatory drug activated 
gene-1; human colorectal cancer through affecting E-twenty six metazoans 
family protein epithelial specific transcription factor-1/early growth response-1 
performance, and human oral cancer by affecting p38 mitogen-activated 
protein kinases signaling pathway expression [25, 37-41].  
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Figure 4. Structure of tolfenamicacid. 
Adapted from Beetstra, 2009. 
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II. HYPOTHESIS AND AIMS 
 
Due to the complicated therapeutic methods with a high reoccurrence of keloid 
scar in clinical treatment, new advanced treatment is clamant [1-4]. Even 
though many questions still remain in regards to TA, TA has been suggested 
as a kind of NSAIDs with high therapeutic index which enjoys a promising 
long-term treatment in treating osteoarthritis, rheumatoid arthritis, migraine, 
and cancer [24, 25, 37-42]. Moreover, as TA is insoluble in water, dimethyl 
sulfoxide (DMSO) was selected as vehicle to dissolve TA for most studies [25, 
37-41]. However, the effect of DMSO was not particularly illustrated based on 
those reports. Thus far, it is very necessary to explore the potential effect of 
DMSO on treating KFS.  
 
This study is to determine the capacity of TA on treating KFs including cell 
proliferation, cell apoptosis, collagen deposition, and collagen type I and 
smad2 protein expression comparing with NFs. Our ultimate goal is to gain the 
information from this project for clinical application to determine if TA is a 
potential therapy for keloid scar. The expecting benefits for the patients may 
contain faster healing time of chronic wound bed with less recurrence thereby 
reducing medical costs of repetitive remedies and surgeries and finally 
elevating the life quality of patients. 
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Overall Hypothesis 
 
We hypothesizes that TA will decrease cell proliferation, induce cell apoptosis, 
and inhibit collagen accumulation of collagen in KFs by down-regulating the 
TGF-ß/Smad signaling.. 
 
Specific Aims 
 
1. To characterize the effect of DMSO on NF and KF apoptosis. 
2. To characterize the effect of TA on NF and KF proliferation. 
3. To test the effect of TA on NF and KF apoptosis. 
4. To test the effect of TA on NF and KF collagen accumulation. 
5. To determine the effect of TA on the expression of collagen type I in NFs 
and KFs. 
6. To explore the influence of TA on the expression of smad2 protein in NFs 
and KFs 
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III. EXPERIMENTAL DESIGNS 
 
To test my hypothesis, I have designed my experimental procedure in a flow 
chart (Figure 5.). Before testing all the steps, I abstracted NFs and KFs from 
tissue samples and incubated them separately. To test specific aim 1, I first 
treated NFs and KFs with different concentration of DMSO for different 
exposure time, respectively. Then I analyzed cell apoptosis caused by each 
concentration and exposure time of DMSO through Annexin V/Propidium 
Iodide (PI) labeling. To test specific aim 2, I treated NFs and KFs with different 
doses of TA for different exposure time, respectively. Next, I analyzed cell 
proliferation after each concentration and exposure time treatment by 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) staining. Based 
on specific aim 1 and 2, it was expected that there is a desirable concentration 
and exposure time of DMSO that is less effective on NFs and KFS, and there 
is a desirable concentration and exposure time of TA that is more effective on 
KFs. By using this particular concentration of DMSO to dissolve TA and use 
the designated treatment time of TA on KFs, I continued to test specific aim 3in 
cell apoptosis by Annexin V/PI labeling, specific aim 4 in collagen production 
by Sirius Red Staining, specific aim 5 in the expression of collagen type I and 
specific aim 6 in the expression of smad2 protein by Western Blot.  
 
 
 
14 
 
 
 
 
 
Figure 5. Experimental design based on my hypothesis and specific aims. 
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IV. MATERIALS AND METHODS 
 
Cell Culture and Treatment 
 
The protocol for obtaining skin tissues during plastic surgeries was approved 
by the ethical institutional review board of Wight State University. Patients 
signed the consent forms. The keloid scar tissue was taken from a 24 year old 
Africa-American with clinical and pathologic evidences of keloid scar confirmed 
as previously described [14, 16]. The normal adult skin samples were obtained 
from a 29 year old Africa-American during plastic surgery [9, 12]. Skin 
specimens were first washed with phosphate-buffered saline (PBS) (Gibco, 
Life TechnologiesTM, USA) three times to exclude erythrocytes, then cut into 
2.5mm x 2.5mm pieces and incubated with 2 ml digestion medium containing 
high glucose Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Life 
TechnologiesTM, USA),5 mg/mL collagenase/dispase II (RocheDignotics, USA) 
and 0.25% trypsin (Invitrogen, Life TechnologiesTM, USA) in 60x15mm tissue 
culture dish for 8h at the condition of 5% CO2, at 37
oC [9, 13, 19]. Then the 
tissue suspension was passed through a 100 mm filter (Biologix Research 
Company, USA) to remove any remaining tissue residuals. The suspension 
was next centrifuged at 300 G for 8 min to obtain cell pellet. This pellet was 
transferred to a T25 cell culture flask cultured with 3 ml total medium 
containing high glucose DMEM, 10%FBS (Gibco, Life TechnologiesTM,USA),1% 
Pen/Strep/Glutamine (Invitrogen, Life TechnologiesTM, USA) in the 
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condition of 5% CO2, at 37
oC. Cells took approximately 3 days to totally attach 
to the bottom and reach to confluence in about 10 days. After cells were 
attached the bottom of the flask, total medium was replaced with fresh total 
medium. During cell growth, every 2 or 3 days medium was changed after PBS 
washing to exclude the flatting dead cells. Once reaching confluence (named 
as Passage 1) cells were detached into a new passage by 0.05% trypsin 
(Invitrogen, LifeTechnologiesTM, USA). Passage 2 to passage 6 cell cultures 
with probably 80%-95% cell confluence were presented in this study [14]. For 
DMSO effect testing, 6 µl DMSO dissolved in 5994 µl total medium for 0.1% 
DMSO, 60 µl DMSO dissolved in 5940 µl total medium for 1% DMSO, 600 µl 
DMSO dissolved in 5400µl total medium for 10% DMSO, and 100% DMSO 
were pre-prepared. For each assay of TA treatment, TA (Cayman Chemical 
Company, USA) was measured for 0.2617g and dissolved in 1ml 100% DMSO 
(Thermo Fisher Scientific, USA) as 1M TA. 900µl 1M TA diluted in 8100µl 100% 
DMSO as tenfold dilution to 10-1M TA. 150µl 10-1M TA diluted in 15ml total 
medium to 10-3M TA. In cell proliferation analysis, 10-3 M TA as original 
concentration was diluted tenfold by total medium, diluted into 10-4M, 10-5M, 
10-6M for TA in this order. In cell apoptosis assay, collagen quantification, and 
western blot of TA treatment group, 3.75ml 10-3M TA as the original 
concentration was diluted by 11.25ml total medium to0.55x10-3M TA. In the 
vehicle treatment group (DMSO group), the same DMSO concentration 
(0.55%) as in the TA treatment group were used to test vehicle effect.  
 
Cell Proliferation Analysis 
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NFs and KFs (0.1x105) were separately seeded into 96-well cell culture plates 
with 200 µl total medium. After 95% confluence, cells were divided into 
different groups for pre-treatment with 200 µl total medium with TA (10-3M, 
10-4M, 10-5M, or 10-6M) for different periods (24h, 48h, or 72h). The MTT kit 
(Invitrogen, Life TechnologiesTM, USA) was used for the proliferation assay. 
Component A in the kit was dissolved by 1 ml PBS to make the MTT solution 
and then stored at 4oC. Component B in the same kit was dissolved by 10ml 
0.01M HCl promptly. After each exposure time, old medium was replaced by 
100 ml fresh medium. Next, 10µlof MTT solution was added into each well and 
incubated for 4h in the condition of 5% CO2, at 37
oC. Then, formazan crystals 
produced by active cells formed in mitochondria through binding succinate 
dehydrogenase which were dissolved in 100µl of component B solution for 
solubilization for 4h in the condition of 5% CO2, at 37
oC.Lastly the absorbance 
was detected at 535 nm in a Packard Fusion spectrophotometer [19]. 
Relatives of Cell proliferation (%) = [OD 535(TA treatment group)/ OD 
535(Non-TA treatment group)] x100.  
 
Cell Apoptosis Assay 
 
NFs and KFs (1.5x105) were separately seeded into 12-well tissue culture 
plates with 2 ml of total medium. For DMSO effect testing, cells with 80% 
confluence were divided into five different groups for pre-treatment with 2 ml 
0%DMSO (total medium), 0.1% DMSO, 1% DMSO, 10% DMSO, or 100% 
DMSO for 24h, 48h, or 72h, respectively. For TA treatment testing, cells with 
85%confluencewere divided into different groups for pre-treatment with 2 ml 
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total medium (Control, Vehicle, and TA) for 48h.Preparing 1X annexin-binding 
buffer (Invitrogen, Life TechnologiesTM, USA) and 1X PI (Invitrogen, Life 
TechnologiesTM, USA)working solution through diluting 200 µl 5X 
annexin-binding buffer with 800 µl DDH2O (dilution at 1:5) and diluting 5 µl 10X 
PI working solution with 50 µl annexin-binding buffer (dilution at 1:10) then all 
solutions were stored at 4oC.After each exposure time for different testing 
group, cells in each well were washed with 2 ml PBS twice and detached by 
300µl0.05% trypsin for 1 min followed by adding 700 µl total medium to stop 
the detachment. Then cells in each well were centrifuged at 400G for 9 min to 
produce a cell pellet. Annexin-binding buffer 100 µl 1X was used to suspend 
the pellet. Suspended cells were stained with 5 µl AnnexinV solution 
(Invitrogen, Life TechnologiesTM, USA) and 1 µl PI working solution for 15-20 
min labeling in the dark. After labeling time, cell apoptosis were detected by 
fluorescence-activated cell sorting(FACS) Calibur Flow Cytometer as soon as 
possible (Accuri C6, Inc., USA), with 488 nm excitation and 530 nm emission 
[38, 39]. 
 
Collagen Quantification 
 
NFs and KFs (1.0x105) were separately seeded into24-well cell culture plates 
with 1 ml total medium. After 80-95% confluence, cells were divided into 
different groups for pre-treatment with 1 ml total medium (Control, Vehicle, and 
TA) for 48h.To analyze collagen production, Sirius Red/Fast Green Staining kit 
(Chondrex, USA) was presented in this assay. After the exposure time, culture 
medium was removed and the cells were washed with PBS. Next, cooled 95% 
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0.5 ml ethanol was added (Decon, Labs, Inc. USA) into each well and 
incubated for 15 minutes at room temperature to fix the cells. Dye 
solution0.2mlfrom the kit was added into ethanol layers which completely 
immersed the fixed layer for staining at room temperature for 1-1.5h. The dye 
solution was removed and the cell layers were rinsed with DDH2O for six times 
and observed under a microscope. After microscope observation, the DDH2O 
were replaced with 1 ml of dye extraction solution from the kit and gently mixed 
until the color was eluted from the cell culture layer. The absorbance at 535 nm 
and 600 nm were read with a Packard Fusion spectrophotometer. Equation: 
Collagen (μg/well) = [OD 535-(OD 600 x 0.291)]/0.037 (Chondrex, 
USA).Relatives of Collagen quantification (%) = [collagen amount (each group 
in NFs or KFs)/ collagen amount (NFs control group)] x 100. 
 
Western Blot Analysis 
 
NFs and KFs (2.5x105) were separately seeded into T25 cell culture flasks with 
3ml total medium. After 85% confluence cells were divided into different 
groups for pre-treatment with 3 ml total medium (Control, Vehicle, and TA) for 
48h. 1tablet of protease inhibitors was added (Roche Diagnostics GmbH, USA) 
into 10ml Lysis buffer (Thermo Fisher Scientific, USA) and stored at 4oC. 
8%SDS-PAGEseparating gel and 10% SDS-PAGE gel were used for western 
blot. SDS-PAGE gel was first ran at 80 V for 30 min (Bio-Rad, PowerPacTM HC, 
USA) as blank running to eliminate the interference caused by gel. Protein 
concentrations were measured by BCA assay. Sixty micrograms of each 
sample with different treatment was mixed with 10 µL of 5X protein sample 
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loading buffer. After loading the samples, proteins were presented at 80 V until 
all the markers appeared. The PVDF membrane was activated initially with 
100% methanol for 15 min, and washed with DDH2O for 1 min, then stored in 
transfer buffer for 10 min. The transfer process from gel to membrane was 
conducted at constant 50mAovernight. The trans-blotted PVDF membrane 
was blocked with blocking buffer (3% BSA; 1X TBS; and 0.05% Tween-20) for 
1 h. It was then incubated with primary antibodies rabbit monoclonal 
anti-human collagen type I (dilution 1:2000,Thermo Fisher Scientific, USA), 
and rabbit monoclonal anti-human Smad2/3 (dilution 1:800, Thermo Fisher 
Scientific, USA) separately for over two nights at 4oC, then washed with TBS-T 
for three times for 5 min each. Anti-rabbit HRP-conjugated secondary antibody 
(dilution at 1:20000, Sigma, USA) was added after washing and incubated for 
another 1 h at room temperature. Next, the membrane was washed in TBST 
for three times for 5minutes each. The membrane was incubated with 
chemiluminescent HRP substrate (Cell Signaling Technology, USA) for 4 min 
in the dark at room temperature before being visualized and then quantified 
using a chemiluminescent detection system (ECL; Bio-Rad, ChemidocTM MP, 
USA). Protein band intensity in each lane was scored in volume intensity and 
was normalized with beta-actin (dilution at 1:4000,Sigma, USA) to standardize 
protein loading[19].  
 
Statistical Analysis 
 
All experiments were performed independently at either four or six times with 
keloid scar culture as well as normal skin dermal culture. Data were analyzed 
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by STATISTICA version 6.0 software package (StatSoft, Inc. USA) and 
expressed as mean ± SEM which was evaluated by applying one-way ANOVA 
between two groups in this study. P<0.05 was considered statistically 
significant for all tests. 
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V. RESULTS 
 
The Dose and Exposure Time Responses of DMSO on Cell Apoptosis in 
NFs and KFs 
 
To determine whether DMSO could induce cell apoptosis on NFs and KFs, we 
performed Annexin-V/PI labeling of fluorescence-activated cell sorting (FACS) 
after applying 0%, 0.1%, 1%, 10%, or 100% DMSO for 24, 48, or 72 hours, 
respectively. Table 1.and Table 2. showed the average events counted in 
DMSO treatment on NF and KF apoptosis. For each analysis, total 10000 
events were counted. The living cells were defined as Annexin V (-) and PI (-); 
early apoptotic cells were defined as Annexin V (+) and PI (-); late apoptotic 
cells were defined as Annexin V (-) and PI (+); dead cells were defined as 
Annexin V (+) and PI (+).From Figure 6, with the addition of concentration of 
DMSO, the proportion of early apoptotic and late apoptotic cells were 
increased. Compared with 0% DMSO (control), only 100% DMSO induced 
both early and late apoptosis significantly in NFs. After 48h treatment (Figure 
7), 10% and 100% DMSO strikingly induced a significant early and late 
apoptosis in NFs. For 72h DMSO treatment group (Figure 8), cell apoptosis in 
1%, 10% or 100% DMSO treatment were increased, especially the percentage 
of early apoptosis. With the addition of exposure time increased (Figure 9), 1% 
DMSO after 72h treatment induced an obvious cell apoptosis compared to 48h 
and 24h in NFs. From Figure 10, with the increasing concentration of DMSO, 
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The proportion of early apoptotic and late apoptotic cells were increased in 
KFs. Compared with 0% DMSO (control), 10% and 100% DMSO induced both 
early and late apoptosis significantly. After 48h treatment (Figure 11), only 100% 
DMSO induced a remarkable early and late apoptosis in KFs. For 72h DMSO 
treatment (Figure 12), 1%, 10% and 100% DMSO increased a striking 
apoptosis percentage, especially the percentage of early apoptosis. With the 
exposure time increased (Figure 13). 1% DMSO group for 72h treatment 
induced an obvious cell apoptosis compared with 24h and 48h in KFs. The two 
figures demonstrated that cell apoptosis of NFs and KFs were induced by 
DMSO in a dose- and exposure time- response way. Lower concentration of 
DMSO (0.1% and 1%) with less exposure time (24h and 48h) did not 
significantly induce cell apoptosis in NFs and KFs. The presented data were 
based on four independent experiments, comparing with non-DMSO treatment 
group in NFs and KFs separately. 
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Table 1. Average events counted of DMSO on cell apoptosis in NFs. For each 
analysis, total 10000 events were counted. The living cells were defined as 
Annexin V (-) and PI (-); early apoptotic cells were defined as Annexin V (+) 
and PI (-); late apoptotic cells were defined as Annexin V (-) and PI (+); dead 
cells were defined as Annexin V (+) and PI (+). 
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Figure 6. The dose responses of DMSO for 24h on cell apoptosis in NFs. 100% 
DMSO with 24h exposure time induced a significant early and late apoptosis in 
NFs. 0: 0%DMSO, total medium; 0.1, 0.1% DMSO; 1: 1% DMSO; 10: 10% 
DMSO; 100: 100% DMSO. *, P<0.05, 100 vs. 0.1; n=4.  
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Figure 7. The dose responses of DMSO for 48h on cell apoptosis in NFs. 10% 
and 100% DMSO with 48h treatment induced both early and late apoptosis in 
NFs, respectively. 0: 0% DMSO, total medium; 0.1: 0.1% DMSO; 1: 1% DMSO; 
10: 10% DMSO; 100: 100% DMSO. +, P<0.01, 10 vs. 0, 0.1, or 1; &, P<0.01, 
100 vs. 0, 0.1, 1, or 10; n=4.  
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Figure 8. The dose responses of DMSO for 72h on cell apoptosis in NFs. 1%, 
10%, and 100% DMSO induced a significant cell apoptosis especially the 
percentage of early apoptosis in NFs. 0: 0% DMSO, total medium; 0.1: 0.1% 
DMSO; 1: 1% DMSO; 10: 10% DMSO; 100: 100% DMSO. $, P<0.01, 1 vs. c or 
0.1; ※, P<0.01, 10 vs. c, 0.1, or 1; §, P<0.01, 100 vs. c, 0.1, or 1; n=4.  
 
28 
 
 
 
Figure 9. The exposure time responses of 1% DMSO on cell apoptosis in NFs. 
1% DMSO with 48h and 72h exposure time induced cell apoptosis in NFs. 1% 
DMSO with 72h exposure time induced an obvious cell apoptosis especially 
early apoptosis in NFs. ※※, P<0.01, 72h vs. 24h or 48h; n=4. 
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Table 2. Average events counted of DMSO on cell apoptosis in KFs. For each 
analysis, total 10000 events were counted. The living cells were defined as 
Annexin V (-) and PI (-); early apoptotic cells were defined as Annexin V (+) 
and PI (-); late apoptotic cells were defined as Annexin V (-) and PI (+); dead 
cells were defined as Annexin V (+) and PI (+). 
 
 
 
 
 
30 
 
 
Figure 10. The dose responses of DMSO for 24h on cell apoptosis in KFs. 10% 
and 100% DMSO with 24h exposure time induced a significant early and late 
apoptosis in KFs. 0: 0% DMSO, total medium; 0.1: 0.1% DMSO; 1: 1% DMSO; 
10: 10% DMSO; 100: 100% DMSO. *, P<0.01, 10 vs. c, 0.1, or 1; #, P<0.01, 
100 vs. c, 0.1, 1 or 10; n=4.  
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Figure 11. The dose responses of DMSO for 48h on cell apoptosis in KFs. 100% 
DMSO with 48h exposure time induced a significant early and late apoptosis in 
KFs. 0: 0% DMSO, total medium; 0.1: 0.1% DMSO; 1: 1% DMSO; 10: 10% 
DMSO; 100: 100% DMSO. +, P<0.05, 100 vs. c, 0.1, 1, or 10; n=4.  
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Figure 12. The dose responses of DMSO for 72h on cell apoptosis in KFs. 1% 
and 10% DMSO with 72h exposure time induced a significant early and late 
apoptosis in KFs. 100% DMSO with 72h exposure time induced a significant 
early apoptosis in KFs0: 0% DMSO, total medium; 0.1: 0.1% DMSO; 1: 1% 
DMSO; 10: 10% DMSO; 100: 100% DMSO. &, P<0.01, 1 vs. c or 0.1; $, 
P<0.01, 10 vs. c, 0.1, or 1; ※, P<0.01, 100 vs. c, 0.1, 1, or 10; n=4.  
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Figure 13. The time responses of 1% DMSO on cell apoptosis in KFs. 1% 
DMSO after 48h and 72h will induce cell apoptosis in KFs. 1% DMSO with 72h 
exposure time induced an obvious early and late apoptosis in KFs. ※※, 
P<0.01, 72h vs. 24h or 48h; n=4.  
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The Dose and Exposure Time Responses of TA on Cell Proliferation in 
NFs and KFs 
 
The effect of TA on NFs and KFs proliferation was evaluated using MTT 
analysis. NFs and KFs were cultured in the presence of TA (10-3M, 10-4M, 
10-5M, 10-6M) dissolved in 1% DMSO for 24, 48, or 72 hours, respectively. 
From Figure 14and 15, at the highest concentration of TA, cell proliferation 
rates appeared to decrease. As the exposure time increased, NF proliferation 
sharply decreased at 10-3M TA. More specifically, as shown in Figure 14., the 
proliferation rate was significantly reduced in NFsat10-3M TA for 48h or 72h 
group comparing at 24h. In KFs, there is no statistical difference on the cell 
proliferation rate between the control group and TA-treated groups in 24h 
testing group (Figure 15.). While after 48h or 72h treatment of TA on KFs with 
the addition of TA, the proliferation rate decreased at10-3M TA. However, this 
concentration decreased cell proliferation in both NFs and KFs as well. To 
further test the effects of TA on NFs and KFs, we selected 0.55x10-3MTA 
with48h exposure time as our testing dosage and exposure time. The two 
figures demonstrated that cell proliferation of NFs and KFs were decreased by 
more than 10-4Mof TA with 48 or 72 exposure time. The presented data were 
based on six independent experiments, comparing with non-TA treatment 
group in NFs and KFs separately. 
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Figure 14. The dose and exposure time responses of TA on cell proliferation in 
NFs. In 48h exposure time group and 72h exposure time group, 10-3M TA 
significantly decreased cell proliferation in NFs. In 10-3M TA treatment group, 
treatment with 48h and 72h exposure time decreased cell proliferation 
significantly. 0, 10-6, 10-5, 10-4, 10-3, 0.55x10-3: M TA was dissolved in 1% 
DMSO.*, P<0.01, 10-3M vs. 0M; +, P<0.01, 48h vs. 24h; #, P<0.01, 10-3M vs. 
0M or 10-4M; &, P<0.01, 72h vs. 24h or 48h; n=6.  
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Figure 15. The dose and exposure time responses of TA on cell proliferation in 
KFs. In 48h exposure time group and 72h exposure time group, 10-3M TA 
significantly decreased cell proliferation in KFs. In 10-3M TA treatment group, 
treatment with 48h and 72h exposure time decreased cell proliferation 
significantly. 0, 10-6, 10-5, 10-4, 10-3, 0.55x10-3: M TA was dissolved in1% 
DMSO. **, P<0.01, 10-3M vs. 0M; ++, P<0.05, 48h vs. 24h; ##, P<0.05, 10-3M 
vs. 0M; &&, P<0.01, 72h vs. 24h or 48h; n=6.  
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The Effects of TA on cell apoptosis in NFs and KFs 
 
To determine whether TA induced cell apoptosis on NFs and KFs, we 
performed Annexin-V/PI labeling of FACS after applying 0.55x10-3MTA 
dissolved in 1% DMSO for 48h.Table 3.showed the average events counted in 
TA treatment on NF and KF apoptosis. For each analysis, total 10000 events 
were counted. The living cells were defined as Annexin V (-) and PI (-); early 
apoptotic cells were defined as Annexin V (+) and PI (-); late apoptotic cells 
were defined as Annexin V (-) and PI (+); dead cells were defined as Annexin 
V (+) and PI (+).According to Figure 16., Annexin V positive and PI positive 
cells were not remarkably increased by TA in NFs while they were significantly 
raised in KFs. Though vehicle effect was exhibited in the NFs, it can be pointed 
out that 0.55x10-3M TA with 48h exposure time induced selectively significant 
apoptosis on KFs compared with non-TA treatment groups in KFs and in NFs. 
Moreover, from Figure 16., we also found that 0.55% DMSO stimulates cell 
apoptosis in NFs and KFs, especially in NFs. The presented data are based on 
six independent experiments and compared with non-TA treatment group in 
NFs.  
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Table 3. Average events counted of DMSO on cell apoptosis in NFs and KFs. 
For each analysis, total 10000 events were counted. The living cells were 
defined as Annexin V (-) and PI (-); early apoptotic cells were defined as 
Annexin V (+) and PI (-); late apoptotic cells were defined as Annexin V (-) and 
PI (+); dead cells were defined as Annexin V (+) and PI (+). 
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Figure 16. The effect of TA on cell apoptosis in NFs and KFs. DMSO induced 
early and late apoptosis in NFs and slightly induced early apoptosis in KFs. TA 
strikingly induced late apoptosis in KFs. C: control, total medium; V: vehicle, 
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0.55% DMSO; TA, 0.55x10-3M of TA was dissolved in 0.55%DMSO. *, P<0.01, 
V vs. C or TA; ##, P<0.05, TA vs. C; &&, P<0.01, TA vs. TA; n=6.  
 
The Effects of TA on Collagen Production in NFs and KFs 
 
Quantitative analysis of Sirius Red fluorescent staining at intracellular and 
extracellular reflects the degree of all types of collagen produced by fibroblasts. 
Therefore, the intensity of red cell with fluorescence presentation indicated the 
amount of collagen produced by cells. By using 0.55x10-3M TA on NFs and 
KFs for 48h, we found that collagen production was significantly reduced in 
KFs (Figure 17.).According to Figure 17., 0.55% DMSO stimulated collagen 
production in NFs and KFs, especially in NFs. In other words, TA did not inhibit 
collagen production significantly in NFs while it obviously decreased the 
collagen deposition in KFs. Additionally, there was a remarkable observation 
about morphological changes in KFs. From Figure 18., the staining signals of 
both intracellular and extracellular were decreased. Stained collagens 
secreted to extracellular were reduced and meanwhile cytoplasm was 
concentrated. These changes eventually decreased cell density in KFs. Based 
on the biases of these data, we demonstrated that 0.55x10-3M TA for 48h 
reduced collagen production in KFs. The presented data are based on four 
independent experiments and compared with non-TA treatment group in NFs. 
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Figure 17. The effect of TA on collagen production in NF and KF after sirius red 
staining. DMSO significantly increased collagen production in NFs. TA 
strikingly reduced collagen production in KFs compared with NFs. C: control, 
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total medium; V: vehicle, 0.55% DMSO; TA, 0.55x10-3M of TA was dissolved in 
0.55% DMSO. *, P<0.01, V vs. C; #, P<0.05, TA vs. V; ##, P<0.05, TA vs. C; 
&&, P<0.01, TA vs. V; n=4.  
 
 
Figure 18. Morphological changes of TA on collagen production in KFs. 
Staining signals of intracellular and extracellular were reduced. Stained 
collagen which secreted to extracellular was decreased and meanwhile 
cytoplasm was concentrated. Eventually, cell density was decreased. 
Observed under 20X microscope after sirius red staining. 
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The Effects of TA on the Expression of Collagen Type I and Smad2 
Proteins in NFs and KFs 
 
The effects of TA on protein expression of collagen type I (Collagen I) and 
smad2 protein in NFs and KFs were evaluated by Western blot. The protein 
level of Collagen I andsmad2 was measured 48 hours later after each 
treatment. From the view of Figure 19.,there was a remarkably increasing 
expression in KFs compared with NFs. TA significantly suppressed the 
expression of collagen type I in KFs compared with the other groups; while the 
inhibition of collagen type I expressed in NFs after TA treatment was 
ambiguous. This result demonstrated that0.55x10-3M TA for 48h inhibits 
collagen I expression significantly in KFs while not effectively in NFs. Besides, 
0.55% DMSO slightly decreased the expression of collagen I in NFs and 
increased collagen I expression in KFs. In Figure 20., TA inhibited Smad2 
expression in both NFs and KFs with more significance in KFs. Meanwhile, 
0.55% DMSO also reduced the expression of Smad2 protein in NFs group 
showed in Figure 20. This data suggested that 0.55x10-3M TA for 48h could 
inhibitsmad2 expression in both NFs and KFs. The presented data are based 
on four independent experiments and compared with non-TA treatment group 
in NFs. 
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Figure 19.The effect of TA on the expression of collagen type I in NFs and KFs. 
DMSO slightly increased the expression of collagen type I in KFs. TA 
significantly inhibited the expression of collagen type I in KFs. C: control, total 
medium; V: vehicle, 0.55% DMSO; TA, 0.55x10-3M of TA was dissolved in 0.55% 
DMSO. +, P<0.05, C vs. C; &, P<0.05, V vs. NFs C; #, P<0.05, TA vs. V; n=4.  
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Figure 20.The effect of TA on the expression of smad2 protein in NFs and KFs. 
DMSO decreased the expression of smad2 protein in NFs. TA significantly 
inhibited the expression of smad2 protein in KFs. C: control, total medium; V: 
vehicle, 0.55% DMSO dissolved in total medium; TA, 0.55x10-3M of TA was 
dissolved in 0.55% DMSO. *, P<0.006, TA vs. C; $, P<0.04, TA vs. TA; n=4.  
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VI. DISCUSSION 
 
Keloid scar, a type of scars, behaves like tumors with uncontrolled expanding 
at wound site and invasion to the neighboring normal skin tissue [16, 20]. It has 
been suggested that keloid scar is a fibroproliferation disease with the 
accumulation of collagen deposition due to the upregulation of TGF-ß/Smad 
signaling in the wound healing process [5, 14, 16]. TA is a NASIDs which 
belongs to the family of fenamate and has been used recently for cancer 
treatments [24, 25, 37-42, 44]. We designed an experiment to determine if the 
administration of TA is able to decrease collagen production in KFs. We also 
want to explore the possible mechanism of action of TA in regulating 
TGF-ß/Smad signaling transduction when treating on KFs. Our study 
demonstrated that TA has the potential to normalize some of the characteristic 
features of KFs such as cell apoptosis and collagen production especially 
collagen type I expression. 
 
Various Concentrations and Exposure Time of DMSO Induced Different 
Apoptotic Results in Human Normal Fibroblasts and Keloid Fibroblast 
 
As TA is insoluble in total medium, a vehicle to dissolve it is certainly 
necessary. Most studies have illustrated DMSO as a universal solvent [25, 
37-41]. However, there is not sufficient data to exclude the effects caused by 
DMSO. Therefore, the influence of DMSO as a vehicle was conducted in our 
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study as preliminary experiment. We tested the effect of various 
concentrations (0%, 0.1%, 1%, 10% and 100%) and exposure times (24h, 48h, 
and 72h) of DMSO on NF and KF apoptosis. We found that 1% DMSO with 
48h exposure time did not significantly induce cell apoptosis. We also found 
that the least concentration to dissolve experimental dosage of TA (10-3M, 
10-4M, 10-5M, 10-6M) is 1% DMSO. Thus far, 1% is the experimental 
concentration of DMSO for continuous studies on KFs. Besides, in our studies, 
we also set a vehicle group to exclude the influence caused by DMSO.  
 
Tolfenamic Acid Decreased Cell Proliferation in Human Normal 
Fibroblasts and Keloid Fibroblasts 
 
We tested the effects of TA on NF and KF proliferation by applying five 
concentrations (10-3M, 10-4M, 10-5M, 10-6M) of TA for 3 different exposure 
times (24h, 48h, 72h) separately. We found that NF and KF proliferations were 
decreased with the 10-3M TA after 48h exposure. This indicated that cell 
proliferation was not significantly affected by TA. In addition, under this 
circumstance, cell proliferation in both NFs and KFs were strikingly reduced. 
One of our expectations is to find a desirable concentration of TA that could 
treat KFs effectively and less toxic to NFs. In cell proliferation assay, our data 
pointed out the concentration which caused half reduction in NF proliferation 
between 10-4and10-3Mof TA with 48h exposure time as our experimental 
condition. Though this concentration of TA with 48h exposure time did not 
show more significant reduction in KFs, we expected there will be more 
significances presenting in other analysis. 
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Tolfenamic Acid Selectively Induced Cell Apoptosis in Human Keloid 
Fibroblasts 
 
To further confirm the effects of this particular does and exposure time of TA is 
the ideal experimental condition, we used0.55x10-3M TA with 48h treatment on 
NFs and KFs to test cell apoptosis. In this concentration of TA, we calculated 
that there is a 0.55% DMSO as a vehicle, so besides total medium as control 
group, we set a vehicle group with 0.55% DMSO to test the effects. We found 
that though 0.55% DMSO induced a proportional apoptosis in NFs and KFs, 
cell apoptosis in KFs after TA treatment induced a selectively significant 
apoptosis compared with NFs. This indicated that cell apoptosis was 
significantly influenced by TA. Thus far, we first suggested that 0.55x10-3M TA 
with 48h treatment was the ideal experimental condition for continuous studies 
on KFs and second TA was able to selectively induce cell apoptosis in KFs. 
 
Tolfenamic Acid Strikingly Reduced Collagen Production in Human 
Keloid Fibroblasts 
 
According to the histological changes in KFs [1-4], reducing collagen 
production is a targeting way to treating keloid scar. In our study, we tested the 
effects of TA on decreasing the accumulation of collagen and furthermore tried 
to explain the relationship between cell apoptosis and collagen deposition. 
Based on our data, high inhibition rate of collagen production was detected in 
KFs after 0.55x10-3M TA for 48h exposure time compared with NFs. Although 
the effect of 0.55% DMSO increased collagen production in NFs, the 
 
49 
production caused by 0.55%DMSO did not show specific significance in KFs. 
Concurrently, after TA treatment, staining signals of intracellular and 
extracellular were decreased. Stained collagen secreted to extracellular was 
decreased with cytoplasm concentrated and thus cell density was decreased. 
Therefore, these outcomes indicated that TA reduced collagen production in 
KFs with high efficiency. This also further pointed out that the inhibitory effect 
of TA on collagen accumulation is associated with inducing cell apoptosis in 
vitro. 
 
Tolfenamic Acid Significantly Inhibited the Expression of Collagen Type I 
in Human Keloid Fibroblasts 
 
In collagen quantification assay, the type of stained collagen is non-specific. 
As studies showed the majority of collagen produced by KFs is collagen type I, 
we particularly test the expression of collagen type I after TA treatment [1, 2, 
16, 17, 19, 20]. Our study showed that there is a remarkably increasing 
expression of collagen I in KFs compared with NFs. Moreover, 0.55x10-3M TA 
for 48h exposure time significantly inhibited the expression of collagen type I in 
KFs compared with NFs in vitro.0.55% DMSO group did not show significant 
inhibitions of the expression of collagen type I in NFs and KFs. This revealed 
that DMSO did not significantly influence the expression of collagen type I and 
the inhibitory effect of TA on collagen accumulation, especially collagen type I, 
is associated with inducing cell apoptosis in vitro. 
 
Tolfenamic Acid Inhibited the Expression of Smad2 Protein in Both 
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 Human Normal Fibroblasts and Keloid Fibroblasts 
 
TGF-ß is a key cytokine of regulating extracellular and intracellular signaling 
pathway. Current studies about TGF-ß signaling pathway downstream 
transduction in KFs suggested that smad family was the fundamental mediator 
influencing nuclear gene expression [16, 19, 20]. The amount of smad family 
accumulated in the nucleus and the duration was coordinated with their target 
promoters for the transcriptional responses. Smad2 is a critical cytokine in 
regulating collagen gene expression which will cause pathogenically 
fibroproliferation during keloid formation [19, 20]. Blocking Smad2 signaling 
pathway could theoretically suppress the production of collagen, thus 
preventing the occurrence of keloid scars. This also implied an accessible way 
in eliminating or blocking the accumulation of collagen in treating KFs. In our 
study, 0.55% DMSO for 48h inhibits smad2 expression in NFs. By combining 
our data together, it suggested that DMSO was able to affect NF activities in 
cell apoptosis and collagen production while the influence in KFs was not 
significant compared with TA treatment. Also, our study illustrated that 
0.55x10-3M TA for 48h inhibits the expression of smad2 protein in both NFs 
and KFs. This signifies that inhibitory effect of TA on smad2 expression in NFs 
and KFs. To our knowledge, there is increased signaling and elevated levels of 
smad complexes in keloid scar, which substantiates the possible model of an 
autocrine positive feedback loop in keloid scar [12,13, 15, 17, 19, 21]. Due to 
the hyperactivity of KF, cell activities such as cell apoptosis and collagen 
production especially collagen type I were significantly increased comparing 
with NF. However, the expression of smad2 protein in both NFs and KFs were 
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inhibited. This possibly suggested that in this keloid sample the expression of 
smad2 protein was undercontrolled by the autocrine positive feedback loop. 
Although there is an over production of collagen type I, the autocrine positive 
feedback loop is regulated by the smad2 signaling transduction in 
TGF-ß/Smad signaling pathway in KFs. TA can break the autocrine positive 
feedback in NFs and lead the expression of smad2 protein reduced. But, with 
the hyperactivity of TGF-ß/Smad signaling and the regulation of autocrine 
positive feedback loop, the inhibition in KFs after TA is not that significant 
compared with NFs. The activity of smad2 and autocrine positive feedback 
loop in KFs expected to conduct in further studies. 
 
The Outlook of Tolfenamic Acid on Treating Keloid Fibroblasts 
 
For further studies, other protein expressions of collagen especially type III 
collagen, smad family treated after TA within more samples, and autocrine 
positive feedback loop in KFs are taken into consideration. At the same time, 
agonists, antagonists and signaling blockers of TGF-ß signaling pathway, for 
example, TGF-ß receptor I blockers, TGF-ß receptor II blockers, 
phosphorylazedsmad family are expected to further confirm the mechanism of 
TA on KFs in the future. In the cell signaling pathway of TGF-ß/Smad, specific 
protein 1 is discovered as the transcription factor that influences the DNA 
binding or DNA associated protein binding for nuclear gene expression. The 
transcription for specific protein 1 is activated by phosphorylated smad family. 
Additionally, the established data showed that specific protein 1 is a new 
targeting approach of transcription factors for keloid scar. TA could also induce 
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apoptosis in cancer cell via being associated with inhibiting specific protein 1 
activities [22, 42, 45, 46]. Hence, specific protein 1 is one cytokine of the smad 
signaling pathway downstream that potentially affected protein expression in 
cellular response. This intriguing idea can be inserted into study the 
mechanism of TA on KFs. 
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VII. CONCLUSION 
 
Generally speaking, our current novel data demonstrated that: 
1)1% DMSO with 48h exposure time did not significantly induce cell apoptosis 
in NFs and KFs;  
2)10-3M TA strikingly decreased cell proliferation in NFs and KFs;  
3) 0.55x10-3M TA selectively induced cell apoptosis in KFs;  
4) 0.55x10-3M TA obviously reduced collagen production in KFs; 
5)0.55x10-3M TA significantly inhibited the expression of collagen type Iin KFs; 
6) 0.55x10-3M TA inhibited the expression of smad2 protein in both NFs and 
KFs. 
 
Therefore, we illustrated that tolfenamic acid induced cell apoptosis and 
inhibited collagen production in keloid fibroblast. TA could be the new 
therapeutically application for treating keloid scars. With the development of 
the advanced Technologies, hundreds and thousands of treatments on keloid 
scar have been reported. However, this is the first time where TA was 
successfully used in vitro to induce cell apoptosis and reduce collagen 
accumulation in KFs. Furthermore, TA is an available commercial formulation 
chemical. Thereby, TA is recommended for clinical trials to confirm our 
findings. 
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